First Hawaiian Bank’s Alnylam Pharmaceuticals ALNY Stock Holding History

First Hawaiian Bank’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,000	Closed	-$941K	–	120
2024 Q4	$941K	Hold	4,000	–	–	0.03%	429
2024 Q3	$1.1M	Hold	4,000	–	–	0.04%	397
2024 Q2	$972K	Hold	4,000	–	–	0.03%	381
2024 Q1	$598K	Hold	4,000	–	–	0.02%	537
2023 Q4	$766K	Sell	4,000 -250	-6%	-$42.6K	0.02%	467
2023 Q3	$753K	Hold	4,250	–	–	0.03%	451
2023 Q2	$807K	Buy	4,250 +227	+6%	+$45K	0.03%	448
2023 Q1	$806K	Sell	4,023 -1,100	-21%	-$231K	0.03%	440
2022 Q4	$1.22M	Sell	5,123 -600	-10%	-$128K	0.04%	310
2022 Q3	$1.15M	Hold	5,723	–	–	0.04%	298
2022 Q2	$834K	Buy	5,723 +23	+0.4%	+$3.26K	0.03%	404
2022 Q1	$931K	Hold	5,700	–	–	0.03%	401
2021 Q4	$967K	Buy	+5,700	New	+$1.06M	0.03%	407
2019 Q1	–	Sell	-238	Closed	-$17K	–	1707
2018 Q4	$17K	Sell	238 -150	-39%	-$11.5K	﹤0.01%	1319
2018 Q3	$34K	Buy	+388	New	+$39K	﹤0.01%	1249

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Hawaiian Bank's ALNY Position: Q1 2025 in Review

First Hawaiian Bank sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2025, closing a stake of 4,000 shares — an estimated $941K sold.

First Hawaiian Bank first reported a position in ALNY in Q3 2018 and held it in 15 quarters. The position peaked at $1.22M in Q4 2022. 627 funds tracked by Wall St. Rank hold ALNY as of Q1 2025.

First Hawaiian Bank reported no remaining Alnylam Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
First Hawaiian Bank sold 4,000 Alnylam Pharmaceuticals shares in Q1 2025, an estimated $941K.
First Hawaiian Bank first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 15 quarters.
First Hawaiian Bank's Alnylam Pharmaceuticals position peaked at $1.22M in Q4 2022.
627 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2025.

Based on First Hawaiian Bank's 13F filing for Q1 2025, filed 3 Apr 2025.